# US 2022/0015406 A1 · Compositions and Methods for Improving Quality of Life in Patients with Autism Spectrum Disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0015406 A1
- Document ID: US20220015406A1
- Status: Published application
- Kind: A1
- Application number: 17/299,367
- Filed: 2020-01-25
- Published: 2022-01-20
- Earliest claimed: 2019-01-25
- Assignees: Flaask, LLC
- Applicants: Flaask, LLC
- Inventors: Andrew R. LEFKOWITZ; Sean FARMER; Ken ALIBEK
- Web page: https://patentgrep.com/patent/US20220015406A1

## CPC

- A23L 33/16: Inorganic salts, minerals or trace elements
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 31/12: Antivirals
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides compositions and methods for treating a subject diagnosed with ASD. In preferred embodiments, the subject compositions comprise tellimagrandin II, glycyrrhizin, monolaurin, selenium, honokiol, a probiotic, and one or more biological amphiphilic molecules, which when administered to a subject, can support immune and/or digestive health, and suppress and/or disable viral pathogenic agents in the body.

## Claims

### Claim 1

A supplement composition comprising tellimagrandin II, glycyrrhizin, monolaurin, selenium, honokiol, and Bacillus coagulans GBI-30 (BC30).

### Claim 2 (depends on 1)

The composition of claim 1, further comprising one or more biological amphiphilic molecules.

### Claim 3 (depends on 2)

The composition of claim 2, wherein biological amphiphilic molecules are selected from glycolipid biosurfactants, lipopeptide biosurfactants and saponins.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the glycolipid biosurfactants are sophorolipids (SLP).

### Claim 5 (depends on 3)

The composition of claim 3, wherein the lipopeptide biosurfactants are surfactin.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the saponins are triterpenoid saponins, steroidal saponins, and/or steroidal glycoalkaloids

### Claim 7 (depends on 3)

The composition of claim 3, consisting essentially of tellimagrandin II, glycyrrhizin, monolaurin, selenium, honokiol, BC30, and one or more biological amphiphilic molecules selected from SLP, surfactin and saponins.

### Claim 8 (depends on 1)

The composition of claim 1, formulated for oral consumption.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition is formulated into a biosurfactant delivery system, wherein a biosurfactant liposome encapsulates the tellimagrandin II, glycyrrhizin, monolaurin, selenium, honokiol and BC30.

### Claim 10

A method for improving the quality of life in a subject diagnosed with autism spectrum disorder, wherein the method comprises administering an amount of a supplement composition comprising tellimagrandin II, glycyrrhizin, monolaurin, selenium, honokiol and BC30 to the subject, wherein the amount is therapeutically-effective.

### Claim 11 (depends on 10)

The method of claim 10, further comprising administering one or more biological amphiphilic molecules to the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the biological amphiphilic molecules are selected from glycolipid biosurfactants, lipopeptide biosurfactants and saponins.

### Claim 13 (depends on 10)

The method of claim 10, wherein the supplement composition is administered to the subject orally.

### Claim 14 (depends on 10)

The method of claim 10, further comprising diagnosing the subject with autism spectrum disorder prior to administering the supplement composition.

### Claim 15 (depends on 10)

The method of claim 10, further comprising performing follow-up tests on the subject to determine whether, and/or to what extent, the subject's quality of life is improved.

### Claim 16 (depends on 10)

The method of claim 10, wherein the subject is infected with one or more of herpes simplex virus 1 (HSV-1), HSV-2, herpes zoster, varicella-zoster virus (VZV), cytomegalovirus (CMV), HHV6, HHV7, HHV8, Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), rubella virus, measles virus, BK virus, JC virus, simian virus 40 (SR40), yellow fever, hepatitis, poliovirus, influenza, pneumovirus, paramyxovirus, coronavirus, HIV, leukemia virus, Simliki forest virus, HPV, Visna virus, vesicular stomatitits virus, respiratory syncytial virus, Dengue virus, and lymphocytic choriomeningitis.

### Claim 17 (depends on 10)

The method off claim 10, further comprising administering an antiviral drug used to treat chronic, congenital, persistent, latent, dormant, acute and/or subacute viral infections to the subject, wherein the antiviral is selected from valacyclovir, acyclovir, famciclovir, ganciclovir, valganciclovir, ribavirin, brivudin, cidofovir, fomivirsen, foscarnet, penciclovir, and vidarabine.

### Claim 18 (depends on 10)

The method of claim 10, used for improving a sign or symptom associated with ASD, wherein the sign or symptom irritability; hyperactivity; inattention; abnormalities in speech, verbal, communication, and language skills; repetitive behavior; stereotypy; compulsive behavior; sameness (resistance to change); ritualistic behavior; obsessive focus on certain topics and/or objects; inability to make eye contact; abnormalities in social interactions and/or understanding of others' feelings; anger issues; emotional outbursts; or self-injury.

### Claim 19 (depends on 10)

The method of claim 10, used for treating and/or preventing a disease, disorder, condition, and/or comorbidity caused by and/or associated with ASD, wherein the disease, disorder, condition and/or comorbidity is anxiety, attention deficit disorder; brain inflammation; viral infections; clinical depression; Tourette syndrome; Fragile X syndrome; obsessive-compulsive disorder; bipolar disorder; learning disabilities; sensory disorders; developmental coordination disorder; disorders of the immune system and/or gastrointestinal system; candidiasis; seizures and/or epilepsy; sleep disorders; or increased risk of cancer.
